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Abstract
Introduction: The objective of this survey was to assess current policies and practice in haemostasis testing among both hospital and outpatient 
laboratories in Republic of Croatia.
Materials and methods: A questionnaire with seventy questions divided into nine sections was created in May 2015. Participants were asked 
about their practice related to test request form, sample collection, prothrombin time (PT) and activated partial thromboplastin time assays, other 
individual haemostasis assays, point-of-care testing (POCT), reporting of coagulation tests results and quality assurance of procedures, the per-
sonnel and other laboratory resources, as well as on issues related to education and implementation of additional coagulation assays in their labora-
tory. The survey was administered and data were collected between June and September 2015. 
Results: A total survey response rate was 104/170 (61.2%). Most respondents were faced with incomplete information on prescribed therapy and 
diagnosis on the test request or inappropriate samples withdrawn on distant locations, but also do not have protocols for handling samples with 
high haematocrit values. Reporting of PT-INR and D-dimer results was different between laboratories. Although almost all laboratories developed 
a critical value reporting system, reporting a value to general practitioners is still a problem. Result on coagulation POCT testing showed that not all 
devices were supervised by laboratories, which is not in compliance with Croatian Chamber of Medical Biochemistry acts. 
Conclusion: Obtained results highlighted areas that need improvement and different practice patterns in particular field of haemostasis testing 
among laboratories. A harmonization of the overall process of haemostasis testing at national level should be considered and undertaken.
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Disorders of haemostasis are associated with sub-
stantial morbidity and mortality, and as such are 
major public health concerns (1,2). In addition to 
being a challenge for clinicians, majority of hae-
mostasis abnormalities are diagnosed by labora-
tory examination of the blood coagulation pro-
cess. Therefore, laboratories have a vital role in di-
agnosis and management of haemostatic disor-
ders (3).
Modern haemostasis laboratory performs a large 
number of distinct assays, and the majority of 
them are screening or specific tests for monitoring 
anticoagulant therapies (3). Prothrombin time 
(PT)/International Normalized Ratio (INR) and acti-
vated partial thromboplastin time (aPTT) are glob-
al clotting assays, frequently employed within 
most laboratories along with platelet count. Be-
sides, tests such as fibrinogen and D-dimer are 
mostly used in order to clarify diagnosis. To pro-
vide further insight into screening tests abnormal-
ities including both bleeding and thrombotic dis-
orders, specific assays for different coagulation 
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components such as factor activity assays, platelet 
function tests (aggregometry) or thrombophilia 
assays are used.
Laboratory assessment of the haemostatic system 
is a major component of clinical management. Due 
to its complex nature, personnel responsible for 
test results interpretation, either laboratory scien-
tists or clinicians, are faced with many challenges.
Testing process variability can affect result accuracy 
and consequently cause diagnostic errors with po-
tentially serious effects on patient outcomes (3, 4).
In Croatia, haemostasis testing is performed both 
in transfusion (TL) and medical biochemistry labo-
ratories (MBL) that are supervised by different pro-
fessional societies. Besides, laboratories operate at 
different healthcare levels, including those in pri-
mary health care (PHC) that mostly perform PT/
INR test only. On the contrary, laboratories within 
secondary healthcare (SHC) and tertiary health-
care (THC) institutions perform a wide range of 
different haemostasis assays. The assumption was 
that substantial variability in laboratory practice 
and policies could exist. Thus, the objective of this 
study was to assess the status of current laborato-
ry practice in coagulation testing among both 
hospital and outpatient laboratories in Croatia.
Materials and methods
In 2015, the Working Group for Laboratory Coagu-
lation operating within the Committee for scientif-
ic and professional development of the Croatian 
Society of Medical Biochemistry and Laboratory 
Medicine developed a strategy in order to evalu-
ate the status of current practices of coagulation 
testing among Croatian laboratories. The first step 
was to identify the coagulation laboratory net-
work, followed by questionnaire design and im-
plementation of a comprehensive online survey.
To establish the coagulation laboratory network, 
the last census of health institutions obtained from 
Ministry of Health and Croatian Institute for Health 
Insurance was compared with data on laboratories 
network obtained from the Croatian Chamber of 
Medical Biochemists (CCMB) and a list of coagula-
tion proficiency testing participants provided by 
the Croatian Centre for Quality Assessment in Lab-
oratory Medicine.
In May 2015, a questionnaire with seventy ques-
tions, divided into nine sections was created. The 
sections comprised: test request form and sample 
collection, testing practices for PT, aPTT and other 
individual haemostasis tests, point-of-care testing 
(POCT), practice in reporting coagulation test re-
sults, practice related to quality assurance (QA) of 
procedures, to personnel and other laboratory re-
sources, issues related to implementation of addi-
tional coagulation tests and education in the labo-
ratory. Detailed instructions for answering the 
questionnaire were provided by each question-
naire. Questions had multiple answers unless stat-
ed otherwise. 
This list of 177 laboratories involved in coagulation 
testing was collated. The questionnaire was sent 
to their e-mail address, providing the option to 
each laboratory of responding electronically by e-
mail or in written form by regular mail. First re-
minder was sent to each participant 3 weeks after 
mailing the survey, and the non-respondents were 
contacted by phone in order to confirm that the 
laboratory had received the survey and also to en-
courage participation. Second reminder was sent 
to all non-responders after another 3 weeks. From 
the initial list of laboratory, an automated response 
on unsuccessful e-mail delivery was recorded from 
7 laboratories. As we were unable to get in contact 
with these, even by phone, and could not get any 
related coherent information we excluded them 
from a final number of laboratories dealing with 
coagulation.
The survey was distributed and data collected be-
tween June and September 2015. All collected in-
formation were processed in accordance with data 
confidentiality.
Statistical analysis 
Data for analysis were obtained by counting. Re-
sults were presented as numbers or relative fre-
quencies (percentages) of total number of partici-
pants or as proportions of observed data alone if 
the overall number of data was <100. Data analy-
ses were performed using Microsoft Excel 2010 
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program (Redmond, Washington: Microsoft, 2010 
Computer Software).
Results
Survey response rate 
Of 170 laboratories in the survey, 104 participants 
returned questionnaires yielding to a total survey 
response rate of 61.2%. Institutions and the health-
care level at which survey participants laboratories 
operate are presented in Table 1. Considering lab-
oratory type 90.4% respondents were MBLs, 
whereas 9.6% were TL.
Test request form and sample collection
The majority of respondents (72.1%) did not have a 
separate coagulation test request form. Most com-
monly provided information on test request form 
Institution Level of the healthcare n (%)
Primary health care centre Primary health care 47/104 (45.2)
General Hospital Secondary health care 18/104 (17.2)
Special hospital Secondary health care 9/104 (8.7)
Clinical Hospital Centres Tertiary health care 9/104 (8.7)
Clinical Hospitals Tertiary health care 3/104 (2.9)
Clinics Tertiary health care 4/104 (3.9)
Institute of Transfusion Medicine NA 1/104 (0.9)
Private institution NA 13/104 (12.5)
Results are presented as ratio (n) and as percentage/frequency (%) of total number of respondents (N=104); NA-not applicable.
Table 1. Institutions and healthcare level of survey participants 
Questions related to test request form for coagulation testing n (%)
1 . Laboratory has a separate coagulation test request form with information on the diagnosis and therapy . 29/104 (27.9)




Low molecular weight heparin therapy
Unfractionated heparin therapy
New oral anticoagulants therapy 
Antiplatelet therapy









2 . Information on therapy is provided independently of having a separate test request form for coagulation 
testing . 54/104 (51.9)







3 . Laboratory is faced with “small and big “ coagulogram request 50/104 (48.0)
Results are presented as ratio (n) and as percentage/frequency (%) of total number of respondents (N=104).
*Percentage was not used as number of subjects is < 100; the sum of individual responses can vary since each participant could 
choose more than one answer.
Table 2. Questionnaire results related to test request form and content for coagulation testing
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Statement related to preanalytical issues of coagulation testing n (%)
1 . The laboratory has defined criteria for rejecting coagulation samples . Most common criteria for 
rejecting coagulation samples stated by participants are*: 99/104 (95.2)
Haemolysed sample
Blood is taken in the tube with wrong anticoagulant
Inadequate ratio of blood and anticoagulant (under or overfilled tube >10%)
Clotted sample
Test tube is not correctly labelled
Mismatch of identification patient’s data on the tube and request form
Transport of samples is outside of the time frame after blood sampling









2 . Concentration of sodium citrate used for coagulation testing
Exclusively 3.2%
Exclusively 3.8%






3 . The laboratory has a defined standard operating procedure for samples with haematocrit values >0 .550 L/L . 25/104 (24.0)
Results are presented as ratio (n) and as percentage/frequency (%) of total number of respondents (N=104).
*Percentage was not used as number of subjects is <100; the sum of individual responses can vary since each participant could 
choose more than one answer.
Table 3. Questionnaire results related to preanalytical issues of coagulation testing
are stated in Table 2. Results related to coagulation 
tubes in use, criteria for sample rejection and exist-
ence of standard procedure for handling samples 
with haematocrit values >0.550 L/L are presented 
in Table 3.
Testing practice for PT
All 104 respondents reported performing PT. In-
formation on reagents in use, detection method 
used for PT testing and PT calibration performance 
is presented in Table 4. Information of Internation-
al Sensitivity Index (ISI) value of PT reagents in use 
was provided by 90.4% laboratories, ranging from 
0.84 to 1.40 (median ISI value 0.99). Only 12/28 re-
spondents stated on how they determined mean 
normal PT (MNPT), mostly using plasma pool 
from healthy individuals (9/12), and only one par-
ticipant stated how MNPT was calculated (the 
arithmetic mean). Determination of MNPT from 
the calibration curve, as a mean value of refer-
ence interval (RI) or by measuring the same sam-
ple in duplicate were individual responses. Half of 
respondents reported INR always as obtained nu-
merical value whereas the other half report INR as 
a numerical value greater than 4.0 to 13.0 (median 
> 6.7). Information on PT result reporting is pre-
sented in Table 4.
Testing practice for aPTT
An estimated 59.6% of respondents reported aPTT 
performance. The assay is performed mainly in 
laboratories not related to PHC institutions (51/57). 
Results related to reagents in use, aPTT results re-
porting, therapeutic interval (TI) for monitoring 
unfractionated heparin (UFH) as well as practice 
regarding additional actions when a prolonged 
aPTT result is encountered in patients not taking 
anticoagulant therapy are presented in Table 5. 
Participants were also asked if they routinely initi-
ate further laboratory workup for the presence of 
lupus anticoagulant (LA), when aPTT correction 
was not obtained after mixing study. All laborato-
ries that declared to perform aPTT mixing study 
(N=23) also reported to initiate further laboratory 
workup. Nevertheless, 10.6% of respondents re-
ported to perform LA diagnostic workup profile 
rather using a lupus-sensitive aPTT reagent (8/11). 
Furthermore, 15/104 (14.4%) respondents declared 
to monitor low molecular-weight heparin (LMWH) 
therapy. Among them, 7 declared to use anti-Xa 
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Statement related to PT testing n (%)
1 . Detection method used for PT testing in your laboratory is:
Optical 50/104 (48.1)
Mechanical 49/104 (47.1)
Not specified 5/104 (4.8)

















Diluting one calibration plasma 19/104 (18.3)
3 . Source of reagent used for PT testing:
Recombinant 45/104 (43.3)
Innovin (Siemens Healthcare Diagnostics, Marburg, Germany) 32/45
RecombiPlasTin/RecombiPlastin 2G (Instrumentation Laboratory, Bedford, USA) 9/45
STA Neoplastine R (Diagnostica Stago, Asnières sur Seine, France) 4/45
Other (human placenta, rabbit brain) 59/104 (56.7)
Thromborel S (Siemens Healthcare Diagnostics, Marburg, Germany) 45/59
STA NeoplastineCl Plus (Diagnostica Stago, Asnières sur Seine, France) 8/59
Hemostat Thromboplastin-SI (Human, Wiesbaden, Germany) 5/59
STA Neoplastine Cl (Diagnostica Stago, Asnieres sur Seine, France) 1/59
4 . Reported International Normalized Ratio (INR) value is*:
Derived from the INR calibration curve 75/104 (72.1)
Calculated from the ISI value provided by the manufacturer 28/104 (26.9)
5 . INR is reported on the test report*:
Always as obtained numerical value 51/104 (50.0)
As a numerical value up to a certain critical limit, and greater than the limit 49/104 (48.0)
6 . PT results of patients who are not receiving oral anticoagulants are reported in:
Proportion and INR 54/104 (51.9)
Proportion 23/104 (22.1)
Percent activity and INR 9/104 (8.7)
Proportion and seconds 4/104 (3.8)
INR 3/104 (2.9)
Percent activity 3/104 (2.9)
Proportion and PT ratio 2/104 (1.9)
Proportion, INR and PT ratio 2/104 (1.9)
Percent activity, INR and seconds 2/104 (1.9)
PT ratio 1/104 (1.0)
Proportion, INR and seconds 1/104 (1.0)
Table 4. Questionnaire results related to prothrombin time testing
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7 . PT reference interval used in the laboratory is provided by:
Harmonized reference intervals published by the Croatian
Chamber of Medical Biochemists 98/104 (94.2)
Reference intervals proposed by the manufacturer 6/104 (5.8)
PT – prothrombin time. INR – international normalized ratio. ISI-international sensitivity index. Results are presented as ratio (n) 
and as percentage/frequency (%) of total number of respondents (N= 104). *The sum of individual responses can vary from 104 
since not all participants responded the question.
Statement related to aPTT testing n
1 . Commercial reagent  used for APTT testing in laboratory is*:
Actin FS (Siemens Healthcare Diagnostics, Marburg, Germany) 38/62
Pathromtin SL (Siemens Healthcare Diagnostics, Marburg, Germany) 15/62
Actin FSL (Siemens Healthcare Diagnostics, Marburg, Germany) 5/62
Cephascreen (Diagnostica Stago, Asnières sur Seine, France) 3/62
CK Prest (Diagnostica Stago, Asnières sur Seine, France) 2/62
aPTT Sclavo (Sclavo Diagnostics International, Sovicille, Italy) 1/62
2 . aPTT result are reported as:
Seconds 7/62
Ratio 8/62
Both seconds and ratio 47/62
3 . Laboratory has established aPTT therapeutic range for monitoring unfractionated heparin therapy 7/62
4 . Actions provided by the respondents when a prolonged aPTT result is encountered in patients not 
taking anticoagulant therapy
Laboratory do not perform aPTT mixing study 36/62
Laboratory performs aPTT mixing study 7/62
Laboratory performs aPTT mixing study only in case of an additional request 11/62
Laboratory performs aPTT mixing study if it is ordered as part of lupus anticoagulant testing 5/62
Laboratory is not informed about aPTT mixing study procedure 3/62
aPTT – activated partial thromboplastin time. Results are presented as ratio (n) of total number of participants performing aPTT 
assay (N=62).
*The sum of individual responses can vary since each participant could choose more than one answer.
Table 5. Questionnaire results related to activated partial thromboplastin testing
assay exclusively whereas even 8 use aPTT for 
monitoring LMWH therapy.
Practice related to the performance of other 
individual haemostasis tests
The most commonly performed haemostasis tests 
among respondents are presented in Table 6. Ob-
tained results showed that even 8.6% of all re-
spondents i.e., 6 PHC and 3 hospital laboratories, 
still perform capillary whole blood clotting time 
(WBCT). 
Although all 47 PHC laboratories perform PT, they-
rarely perform aPTT (11/47) or fibrinogen (4/47). 
Specific haemostasis tests such as coagulation fac-
tor activities, factor inhibitor assays, or thrombo-
philia test panel, as well as other assays presented 
in Table 6 are limited to a small number of mostly 
specialized coagulation laboratories in SHC and 
THC institutions.
Almost half of the respondents performed fibrino-
gen assay and all of them determined fibrinogen 
activity assay (51/51). Among them, 1/51 laborato-
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Coagulation test performed in the 
laboratory is:
n (%)
Prothrombin time (PT) 104/104 (100)
Activated partial thromboplastin time (aPTT) 62/104 (59.6)
Fibrinogen 51/104 (49.0)
D-dimer 42/104 (40.4)
Antithrombin (AT) 25/104 (24.0)
Thrombin time (TT) 24/104 (23.1)
Bleeding time(BT) 22/104 (21.2)
Protein C (PC) 13/104 (12.5)
Coagulation factors 12/104 (11.5)
Platelet aggregation 12/104 (11.5)
Lupus anticoagulant (LA) 11/104 (10.6)
Capillary whole blood clotting time (WBCT) 10/104 (9.6)
Protein S (PS) 9/104 (8.7)
Coagulation factor inhibitors 8/104 (7.7)
Euglobulin clot lysis time 8/104 (7.7)
Plasminogen 7/104 (6.7)
Thrombophilia testing 7/104 (6.7)
Heparin assay (anti-Xa activity assay) 7/104 (6.7)
Fibrin(ogen) degradation products (FDP) 5/104 (4.8)
Fibrin monomer – ethanol test 3/104 (2.9)
Activated clotting time (ACT) 1/104 (1.0)
Results are obtained as ratio (n) and as percentage/frequency 
(%) of total number of respondents (N=104). The sum of 
individual responses can vary from 104 since each participant 
could choose more than one answer.
Table 6. Number of the laboratories that perform particular co-
agulation tests among the survey respondents
ry reported also performing antigen assay and 
4/51 derived fibrinogen method. The derived fi-
brinogen results were reported from 2 laborato-
ries, only in patients not taking OAT.
D-dimer methods in use along with measurement 
units and cut-off values are presented in Table 7. 
All 42 laboratories used fixed D-dimer cut-off val-
ues and the most commonly used values were 0.5 
mg/L DDU (D-dimer units) and 0.5 mg/L FEU (fi-
brinogen equivalent units) (Table 7).
Results related to testing practices for new oral an-














mg/L FEU 0.5 4
mg/L 0.05 1
mg/L FEU 4.5 1




µg/L FEU 500 4
Vidas (5)
mg/L FEU 0.5 4





mg/L FEU 0.5 1
Roche 
cardiac (3) mg/L 0.5 3
Nycocard (2) mg/L 0.3 2
Olympus (2) mg/L 0.5 2
Abbott (1) mg/l 0.05 1
IL-D-dimer 
HS (1) µg/L 500 1
FEU - fibrinogen equivalent unit. N - number of laboratories. 
*Measurement units not assigned with abbreviation FEU are 
D-dimer units (DDU).
Table 7. Questionnaire results on D-dimer commercial re-
agents, measurement units and cut-off values.
Point of care practices
An estimated 9.6% respondents stated that coagu-
lation POCT devices (N=18) are in use in their labo-
ratories or/and medical facilities (Table 9). Most of 
POCT users operate within SHC and/or THC facili-
ties (9/10). Along with laboratories, clinical depart-
ments using coagulation POCT devices are: inten-
sive care units (3/10), Cardiac Surgery Department 
(2/10), Paediatric Department (2/10) and operating 
rooms (1/10). 
Considering PT-INR POCT devices, 4/5 respond-
ents stated its use for monitoring OAT only, and all 
stated use of the same TI as their central laborato-
ries. One laboratory stated that POCT results ob-
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Table 8. Questionnaire results related to testing practices for 
new oral anticoagulants (NOACs)
Statement related to testing practices for 
NOACs:
n(%)
Laboratory is aware of the issue, but does not 
perform it yet 29/104 (27.9)
Laboratory is not informed with the 
possibilities of monitoring NOACs 21/104 (20.2)
Laboratory did not declared at all testing 
practices for NOACs 20/104 (19.2)
Laboratory has implemented test for 
assessing therapy with NOACs 5/104 (4.8)
Laboratory has implemented guidelines for 
assessing therapy with NOACs 2/104 (1.9)
Results are presented as ratio (n) and as percentage/
frequency (%) of total number of respondents (N= 104). The 
sum of individual responses can vary from 104 since not all 
participants responded the question.
POCT device N*
Device is under 
laboratory supervision
yes no
Prothrombin time – INR 
monitoring device 5 5 0
Activated clotting time 
monitoring device 3 1 2
D-dimer device 2 2 0
Thromboleastometer 5 2 3
Aggregometer 3 2 1
Total 18 12 6
Results are presented as number of positive (yes) or negative 
(no) answers. INR – international normalized ratio. 
*N-number of point-of-care devices in laboratories or related 
medical facilities.
Table 9. Questionnaire results related to point-of-care testing 
(POCT) practices
Coagulation laboratory report contains n (%)
Measurement units 97/104 (93.3)
Sample remarks 90/104 (86.5)
Reference intervals 95/104 (91.3)
Therapeutic intervals 74/104 (71.2)
Notice on inability to perform certain analysis 53/104 (51.0)
Recommendations for further testing 20/104 (19.2)
Result interpretation 10/104 (9.6)
Treatment recommendations 6/104 (5.8)
Drug interactions 5/104 (4.8)
Suggested diagnosis 5/104 (4.8)
Testing methodology/reagents 4/104 (3.9)
Recommendations for family members 
testing 2/104 (1.9)
Results are presented as ratio (n) and as percentage/
frequency (%) of total number of respondents (N=104). The 
sum of individual responses can vary from 104 since each 
participant could choose more than one answer.
Table 10. Questionnaire results related to laboratory report 
content
tained outside the laboratory are integrated into a 
central laboratory test report.
Regarding internal quality control (IQC) material, 
respondents stated equal use of lyophilized plas-
ma (4/10) and/or electronic control (3/10), with fre-
quencies: once per week (3/10), followed by once 
per month, with reagent lot change or before each 
analysis. Information on QA and RI for POCT devic-
es not supervised by laboratories was not provid-
ed (6/10).
Inquiries made by outpatients on how to use POCT 
PT-INR self-monitoring devices was noted by 
15.4% laboratories. Moreover, one laboratory re-
corded a complaint on unacceptability of analys-
ing PT-INR exclusively from venous plasma sam-
ples, from a patient living abroad who needed the 
service. 
Practice related to reporting coagulation test results
Results related to test report content are present-
ed in Table 10. When considering critical values, 
55.8% laboratories reported analysis repetition 
along with its documentation. Obtained critical 
values are reported to the physician by phone 
with (66.3%) or without (24.0%) documentation of 
the relevant reported information. Most respond-
ents (92.3%) used CCMB recommendations, 
whereas two laboratories used other documents 
or expert opinions. 
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Quality of procedures is mainly assured by: n (%)
Periodic calibration of all instruments 87/104 (83.7)
Outputting results along with reference intervals 75/104 (72.1)
Comparing patients results with previous 
results (delta check)
73/104 (70.2)
Validation or verification of a new method 
when introducing it in routine practice
68/104 (65.4)
QC analysis in duplicate 35/104 (33.7)
Patient analysis in duplicate 26/104 (25.0)
Periodical evaluation of critical values 17/104 (16.3)
Consensus with clinicians regarding critical values 15/104 (14.4)
Checking the platelet number after sample 
centrifugation
5/104 (4.8)
QC – quality control. Results are presented as ratio (n) and as 
percentage/frequency (%) of total number of respondents 
(N=104). The sum of individual responses can vary from 104 
since each participant could choose more than one answer.
Table 11. Questionnaire results related to quality assurance 
(QA) of procedures
Internal quality control (IQC) procedures n (%)
1 . Daily IQC check by commercial control plasma is performed*
Simultaneously at normal and pathological levels
By intermittent use of normal and pathological levels alternately day by day




2 . Frequency of IQC check*
Before each batch of samples
Every 24 hours (at the beginning of each day)






3 . Daily IQC check by patient plasma*† 13/104 (12.5)
Exclusively as daily control following IQC with commercial plasma prior to sample series of PT, aPTT and fibrinogen
For inter/intralaboratory agreement between different analysers of routine coagulation tests
12/13
2/13
4 . Reported storage conditions of patient plasma used for IQC*†
Use of fresh samples
Freezing samples
 - Maximum frozen time period is 24 hours
 - Maximum frozen time period is 72 hours 
 - Double plasma centrifugation prior to freezing
 - Not specified
Storage at 2-8 °C









PT – prothrombin time. aPTT – activated partial thromboplastin time. Results are presented as ratio (n) and as percentage/
frequency (%) of total number of respondents (N=104). 
*The sum of individual responses can vary since each participant could choose more than one answer. 
†Percentage was not used if number of subjects is < 100.
Table 12. Questionnaire results related to internal quality control (IQC) procedures
Practice related to quality assurance of procedures
Results related to procedures used in order to as-
sure quality of testing are presented in Table 11. 
Practice related to IQC procedures is presented in 
Table 12.
Practice related to personnel and other laboratory 
resources
Results on emergency testing service availability, 
responsibilities, competences, consulting and rec-
ommendations in use, as well as practice problem 
solving are presented in Table 13. In 51.9% re-
spondents, available emergency test panel was 
created on basis of CCMB policy documents.
Implementation of additional coagulation tests and 
further education
An estimated 61.5% of respondents were satisfied 
with a currently performed coagulation panel in 
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Statement n (%)
1 . Availability of emergency test service*
8 hours through working days 
24 hours on week




2 . Responsible for implementation of coagulation testing in laboratory is†:
Medical biochemists, specialist
Medical biochemists, master
Medical doctor, specialists in transfusion medicine





3 . Staff competence is assured by†:
Successful QC performance and if needed, documenting corrective actions
Participating in professional and/or scientific meetings in Croatia
Reviewing  manual procedures
Direct observation of the task
Study of available literature
Analysing unknown samples






















6 . Comments on coagulation test report are provided by†
Medical biochemists, specialist
Medical biochemists, master






7 . Laboratory operates within institution that have consultant haemostasis disorder expert(s) 23/104 (22.1)
8 . Laboratory operates within institution that has specialized anticoagulation clinic 18/104 (17.3)
9 . Laboratory operates within institution that has department for bleeding disorder 17/104 (16.3)
10 .  Daily practice problems are solving by*
Personal contact
Review of literature


















QC – quality control. CCMB – Croatian Chamber of Medical Biochemists. Results are presented as ratio (n) and as percentage/
frequency (%) of total number of respondents (N=104). 
*The sum of individual responses can vary from 104 since not all participants responded the question.
†The sum of individual responses can vary from 104 since each participant could choose more than one answer.
Table 13. Questionnaire results related to personnel and other laboratory resources
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their laboratories with respect to institution needs. 
A need to introduce additional coagulation test(s) 
was noted in 38/104 (36.5%) respondents. Among 
respondents from PHC need to introduce aPTT 
(13/15) fibrinogen (5/15) and D-dimers (5/15) was 
noted. Respondents belonging to SHC and THC 
mostly stated need to introduce certain special-
ized assays, such as NOACs determination (7/23), 
tromboelastometry (4/23), platelet aggregation 
(3/23), anti-Xa activity (3/23), LA (3/23), thrombo-
philia panel (3/23), AT (3/23), PC (3/23), PS (3/23), 
heparin induced thrombocytopenia (HIT) (2/23), 
TT (2/23), coagulation factors VIII (FVIII) (2/23) and 
IX (FIX) (1/23), antiplatelet antibodies (1/23). 
Finally, participants were asked to give opinions 
on the most important problem they encounter in 
daily practice related to haemostasis testing. Of all 
received responses (42/104), sample quality was 
stated as the most common problem (17/42), fol-
lowed by lack of appropriate data on prescribed 
therapy and diagnosis on test request (10/42) and 
incorrect test requesting (4/42). Other problems 
were less common and are presented in Table 14.
Quality of samples
Quality of samples withdrawn in GP office, hospital wards, Home Care or other collaborating institutions at distant locations: 
 - clotted samples 
 - samples with inadequate blood volume 
 - haemolysis
 - delivery of samples out of recommended time frame
 - lipemic samples
Therapy and diagnosis 
Lack of data on diagnosis and/or prescribed anticoagulant therapy 
 - on the test request from clinicians
 - on the test request shipped via CEZIH’s 
Test results are not in concordance to therapy stated on the test request 
Problems related to knowledge on anticoagulant therapy 
 - impact of therapy on certain coagulation assays is not clear, especially for thrombophilia screening test panel 
The purpose of INR is not clear
Result reporting
Clinicians show no respect to opinion on coagulation tests results
 - if critical PT value for outpatients is obtained, urgent reporting results could be delayed due to GP working time
Test ordering 
Unselective test requirements
 - especially for specialized haemostasis tests and according to the results of screening tests (no proper clinical indication)
Incorrect test requesting from primary care practice 
 - for example, instead of anti-Xa activities factor X is required 
Ordering of coagulogram without specifying any test
Reagent quality
Rationalization on reagent consumption 
Stability of reagents and control samples if unpredictable low number of request occurred
Harmonization 
Test results are not in concordance (harmonized) to the results obtained in other institutions possibly due to different 
methodology
Analyzer issues
Inappropriate space for coagulation analysers and coagulation test performance
Analysers with the optical measurement principle
 - difficulties in obtaining results when plasma turbidity occurred due to lipemia or other reasons
CEZIH-central health information system in Croatia. GP-general practice. INR-international normalized ratio. PT-prothrombin time.
Table 14. Questionnaire results related to most common problems encountered in daily practice
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Discussion
The purpose of this survey was to find out how 
Croatian hospital and outpatients laboratories 
handle coagulation testing issues. Obtained re-
sults confirmed the assumption that different 
practice patterns exist among laboratories, point-
ing to a need for harmonization of the overall hae-
mostasis testing process. 
This survey showed that majority of laboratories 
do not have separate coagulation test requests, 
which is certainly not surprising due to wide im-
plementation of information systems in medical 
facilities through the country. However, the main 
problem that respondents encountered was not 
related to request type, but to lack of information 
on diagnosis, prescribed anticoagulation therapy, 
or too general requests such as “small and big co-
agulogram“. Although definition on such coagulo-
grams doesn´t exist, by a tradition the “small” co-
agulogram is considered to comprise PT and APTT, 
whereas addition of TT, fibrinogen and/or coagu-
lation factors assays is considered as “big” coagu-
logram. Looking for supplementary information is 
time-consuming and could also result in addition-
al costs due to unnecessary (re)testing. More com-
prehensive collaboration between general practi-
tioners (GPs) and hospital specialists that send lab-
oratory requests should be considered. 
Almost all respondents defined criteria for rejec-
tion of inappropriate coagulation samples, leading 
to a better overall response rate compared to 
study of Shanganian et al. However, poorer results 
were obtained for criteria such as outside time-
frame transport of samples and non-adequate 
temperature storage (5). Sample quality is influ-
enced by processing and storage and any delay in 
transportation could lead to prolongation of 
screening times or factor activity loss (4,6). There-
fore these criteria should be implemented in the 
existent procedures. 
This survey revealed that some laboratories still 
use 3.8% citrate tubes which are not in compliance 
with current recommendations (7). The results 
from these samples may be overestimated espe-
cially when inappropriate sample volume is ob-
tained or if RI based on results derived from 3.2% 
citrated tubes are applied (4-7). Furthermore, most 
respondents did not define a standard procedure 
for handling samples with haematocrit values 
>0.550 L/L, indicating that they were not fully 
aware that failure of adjusting citrate in such sam-
ples can lead to erroneous results as citrate excess 
could  increase measured clotting times (8).
Our findings related to coagulation tests perfor-
mance were similar to other international surveys 
which also documented PT and aPTT as the most 
commonly performed coagulation assays (5).
PT expressed as INR should be used for OAT moni-
toring and reliable INR determination is mandato-
ry. As variable INR values in the same plasma sam-
ple could be obtained on different coagulometers, 
ISI calibration of all routinely used reagents is very 
important (9). This survey showed that most re-
spondents use PT reagents derived from human 
placenta and rabbit brain although recombinant 
tissue factor reagents have better sensitivity to 
factor deficiencies and plasma samples from pa-
tients treated with OAT (10). Respondents mostly 
determine INR values from the specific INR calibra-
tion curve, which is in concordance with currently 
approved CLSI guidelines (11). General consensus 
regarding optimal ISI value is still not agreed, but-
certain societies recommend ISI values <1.20 due 
to precision improvement in INR determination 
(10,12). Declared ISI values of reagents currently in 
use among our respondents were even lower 
(0.84-1.40; median 0.99) compared to previously 
published surveys, showing that Croatian labora-
tories follow recommendation provided in the doc-
ument Harmonized RI published by CCMB (5, 13-15).
Although almost all respondents used harmo-
nized PT RI provided by CCMB (15), unexpected 
findings were obtained on result reporting for pa-
tients not receiving OAT, as half respondents stat-
ed to report INR along with PT proportion. Only 
22.1% respondents report it just as proportion. 
The main reason for non-selective INR reporting 
could be incomplete information on therapy and 
diagnosis, as survey results showed that this infor-
mation are usually not provided on test request 
form. Therefore, an obvious need for urgent im-
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provement in obtaining relevant information on 
anticoagulant therapy should be considered as an 
important prerequisite for adequate PT result re-
porting in patients with and without OAT.
Half of the respondents report INR always as ob-
tained numerical value whereas the other half re-
port INR as numerical value up to a certain critical 
limit, and greater than the limit afterwards. There 
were 16 limit values ranging from 4.0 to 13.0 (me-
dian 6.7) reported, similar to a study of Howanitz 
et al. who reported 18 different critical value limits 
ranging from 2.6 - 10.0 (median 4.5) (14). As report-
ing of obtained critical INR value could be confus-
ing to physicians, we could agree with Howanitz et 
al. that median value of all laboratories should be 
considered for harmonizing INR reporting (14,16).
This survey showed that aPTT is performed in 
much lower proportion than in other national sur-
veys including hospital laboratories only. However, 
when results were restricted to SHC and THC labo-
ratories almost all of them perform aPTT, similar to 
another national survey (98.6%) evaluating only 
hospital laboratories (5).
This survey also revealed that not all laboratories 
performing aPTT, report results both as seconds 
and ratio. Although reporting of aPTT results in 
seconds only is useful for patient’s management, it 
can lead to inappropriate result comparison be-
tween different laboratories. As aPTT reagents dif-
fer considerably in their composition variability 
i.e., phospholipids and activators, leading to differ-
ent UFH and LA sensitivities, aPTT ratio, a calculat-
ed parameter with unique RI independent of the 
reagent used should also be stated on the test re-
port (15).
Our results related to aPTT performing practices in 
patients treated with UFH are quite different from 
others. In a Canadian survey even 66% laborato-
ries had established individual aPTT TI and 47% 
laboratories verified this range with heparinised 
samples (17), similar to an American survey show-
ing that 58.8% hospital laboratories use aPTT TI for 
UFH (5). On the contrary, only 7/62 of our respond-
ents have a defined aPTT TI for UFH monitoring. 
However, different investigations demonstrated 
that standardization between laboratories using 
aPTT for monitoring UFH therapy is quite poor. 
Each laboratory should determine their aPTT rea-
gent sensitivity to UFH and establish local heparin 
TI for every new reagent lot, reagent type or in-
strument which is very complicated in routine (11, 
18, 19).
LMWH use has at least partly suppressed many 
aPTT testing issues in the context of heparin moni-
toring and replaced UFH as the preferred option in 
many clinical situations (19). As expected, survey 
respondents from Clinical Hospital Centres and 
Clinical Hospitals declared to use exclusively anti-
Xa assay, while smaller hospital laboratories use 
aPTT for monitoring LMWH therapy. Valuable 
guidelines recommend the chromogenic anti-Xa 
assay as the only method for LMWH monitoring. 
LMWHs does not exhibit an adequate impact on 
aPTT (18,20), since their anticoagulant action is 
mostly achieved by inhibiting activated FX rather 
than thrombin or activated FIX. Therefore, use of 
an inappropriate aPTT assay for LMWH monitoring 
could potentially have an adverse clinical out-
come. 
Mixing studies are often performed in order to de-
termine whether PT or aPTT prolongation is due 
to factor deficiency or to presence of a circulating 
specific or nonspecific inhibitor such as LA (21). 
This survey showed that more than half of labora-
tories performing aPTT do not offer aPTT mixing 
study or offer it occasionally when an additional 
order is placed for patients with a prolonged aPTT 
not receiving anticoagulant therapy and/or as a 
part of LA workup testing. Recent LA testing 
guidelines from the International Society on 
Thrombosis and Haemostasis (ISTH) stress that 
mixing test should be performed when prolonged 
aPTT is found (22). Furthermore, mixing test 
should always be performed with LA-sensitive rea-
gent, as false negative results may be obtained us-
ing relatively LA-insensitive reagents. Majority of 
our survey respondents performing LA testing de-
clared to use LA-sensitive reagents that is in con-
cordance with current recommendations (22).
Several laboratories stated WBCT performance, 
despite the well-known fact that WBCT is an out-
dated assay, replaced for years with PT and aPTT 
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as part of patient’s preoperative evaluation. Be-
sides, bleeding time (BT) is still used as a screening 
test for the diagnosis of some inherited platelet 
function disorders. As application of both BT and 
WBCT in preoperative analysis is highly questiona-
ble due to low sensitivity and low negative predic-
tive value, their use in routine preoperative evalu-
ation is not recommended (23), and should un-
doubtedly be replaced with platelet count, PT and 
aPTT.
Almost half of survey respondents declared to 
perform the fibrinogen assay, all by using the func-
tional activity assay known as Clauss fibrinogen as-
say. Furthermore, only minor number of respond-
ent declared to perform fibrinogen antigen assay 
and derived fibrinogen method. The use of fibrin-
ogen antigen assays that measure protein concen-
tration is limited to the evaluation of hereditary 
dysfibrinogenemias where there is a discrepancy 
between functional activity and antigen levels 
(24). Further, literature data have shown great con-
troversy regarding suitability of derived fibrinogen 
method for clinical use due to method inaccuracy 
compared to the Clauss method (25-28). Therefore 
Clauss functional fibrinogen assay appears to be a 
method of choice for general use in clinical labora-
tories (29).
Our survey results showed considerable variability 
in reporting D-dimer results, either in FEU or DDU 
units. It must be emphasized that D-dimer values 
expressed in FEU are approximately two-fold high-
er than those expressed in DDU meaning that 1.0 
mg/L FEU corresponds to 0.5 mg/L DDU. Moreo-
ver, we identified a number of different D-dimer 
measurement units currently in use that could 
have a confusing effect on clinicians, when receiv-
ing different reports from neighbour’s laborato-
ries. For example, the value of 0.5 μg/mL corre-
sponds to 500 μg/L or 0.5 mg/L, which is same as 
500 ng/mL. D-dimer cut-off values are established 
by reviewing high risk candidates undergoing ob-
jective testing and test sensitivity and specificity 
should be optimized to make it clinically useful. 
Thus, each laboratory should establish its own cut-
off value and not rely on manufacturer’s recom-
mended value or validation in another laboratory. 
As the main criteria for establishing the cut-off is a 
high negative predictive value, it should be always 
kept in mind that the value of D-dimer testing is 
the absence of elevated D-dimer. The most com-
monly used fixed D-dimer cut-off values in our 
survey were 0.5 mg/L and 0.5 mg/L FEU.
D-dimer levels rise considerably with age and the 
use of age-adjusted cut-off values is increasingly 
discussed as improvement of specificity without 
too much compromising sensitivity (30). In this 
survey, no laboratory appeared to use age-adjust-
ed cut-off values. Recent international survey of 
Lippi et al showed that 93% of laboratories use a 
fixed D-dimer cut-off value, whereas only 7% labo-
ratories use age adjusted cut-offs (31). Evidences 
obtained in both surveys underline the need for 
further standardization in D-dimer result report-
ing. In general, D-dimer testing lacks standardiza-
tion all over the world since there is still no stand-
ardized measurement unit, unique monoclonal 
antibody and calibrator (32, 33). Thus results, RI 
and clinical cut-off values cannot be extrapolated 
between methods. Obviously, an effort should be 
directed towards harmonization of available com-
mercial D-dimer methods.
Furthermore, we examined current status related 
to guidelines for assessing therapy with NOACs. 
NOACs are considered to be more convenient for 
use compared to conventional anticoagulants, 
since dose adjustment and monitoring are not re-
quired for the majority of patients. However, one 
of the challenges of using these drugs is that they 
have a different impact on routine coagulation 
test results, such as PT or APTT which are certainly 
not suitable for their monitoring. Interpretation of 
routine global assays may be a problem as abnor-
mal results may be misinterpreted by non-expert 
clinicians. The biggest educational challenge will 
not be with clinicians who prescribe and manage 
anticoagulant therapy, but with those not routine-
ly involved in anticoagulant care, who will encoun-
ter an increasing number of patients incidentally 
taking NOACs (34). Although rarely, in several cir-
cumstances such as overdose or in patients with 
impaired renal function, assessment of the NOACs 
anticoagulant effect will be required (35). At pre-
sent, appropriate tests for NOACs are not available 
in most laboratories, and it is unlikely that many 
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laboratories could implement these assays in rou-
tine practice. Results of our survey found that al-
most all respondents did not implemented guide-
lines for assessing NOACs therapy at present. This 
finding confirms the fact that there is a clear need 
for education and implementation guidelines re-
lated to the laboratory role of treatment with 
NOACs. 
According to survey results, coagulation POCT de-
vices were in use in 9.6% of medical facilities only.
However, the most important finding was that 
POCT devices such as tromboelastometry (TEM) or 
activated clotting time (ACT) mostly are not under 
the supervision of MBLs, which is not in compli-
ance to CCMB recommendations (36). Similar to 
CCMB, British Committee for Standards in Haema-
tology guidelines clearly state: “the head of the 
clinical laboratory or a POCT coordinator must 
take responsibility for all aspects of the POC test-
ing, including QC and training” (37,38). As ag-
gregometry and TEM are becoming a standard di-
agnostic tool in perioperative and postoperative 
acute bleeding management, an increased usage 
in certain departments could be expected. There-
fore, an obvious need for urgent collaboration on 
POCT issue between laboratories and clinicians 
should be considered.
It is surprising that only 16 laboratories received a 
request from patients related to PT-INR self-moni-
toring devices. These devices are commonly used 
in some western countries and recent investiga-
tions showed that they are an acceptable alterna-
tive to laboratory INR monitoring (39). They are 
certainly less time consuming for patients and sev-
eral reviews showed better mean time in thera-
peutic range for self-monitoring patients (40). 
When considering IQC performance, most re-
spondents meet recommended minimum criteria 
(41), but surprisingly, 12.5% of respondents report-
ed use of patient plasma as an IQC material in con-
junction with commercial controls (41). Patient 
plasma is an important factor in analyzer compari-
son, but due to many circumstances, e.g., stability 
of factor activities in fresh plasma, influence of 
storage temperature and processing time on the 
results we believe that it would not be appropriate 
to use it exclusively as IQC material (6).
This survey showed that implementation of coag-
ulation testing is a MBs responsibility both in MBL 
and TL; although in TL supervision is done by 
transfusiologist. This is in concordance with a for-
mal organisation in Croatia and quite different 
compared to EU or U.S. laboratories where haema-
tology specialists are mostly involved in imple-
mentation of coagulation testing (5, 42).
Our survey showed that most laboratories are 
compliant with CCMB recommendations for test 
reporting (43). Result interpretation or recommen-
dation for further testing is implemented in small 
number of specialized coagulation laboratories. 
Further, consulting service related to coagulation 
testing are provided by only 36.5% of laboratories. 
This is partly due to the traditional view that con-
sultancy should not be provided by laboratory 
staff and the fact that therapy dose change is not 
within a MB competence. Furthermore, notes on 
testing methodology is provided by few laborato-
ries only, mainly when reporting D-dimer results. 
However, good knowledge of all circumstances 
surrounding the performed test is precondition 
for proper information to be given on test report. 
As our survey showed that medical doctors are 
rarely involved in coagulation laboratory work, 
more collaboration with clinicians and develop-
ment of appropriate policies in post analytical 
phase of coagulation testing must be considered 
(5, 43).
This survey showed that availability of emergency 
coagulation testing depends on the level of the 
health care service, i.e. 8 hours through working 
days in PHC and 24 hours 7 days a week in smaller 
number of SHC/THC laboratories. The Emergency 
test panel is in compliance with CCMB recommen-
dations in most laboratories that adhere to the 
CCMB document on critical values (17,43). Most 
laboratories report critical values to physicians by 
phone, although not all of them regularly docu-
ment the call, which is similar to results from other 
surveys (5,16,17). The most common problem on 
critical values reporting, encountered by partici-
pants was critical result reporting to GPs due to 
shift work. As an established system of critical val-
ues reporting is an important laboratory quality 
indicator, design of comprehensive guidance in re-
Biochemia Medica 2017;27(1):199–216  http://doi.org/10.11613/BM.2017.022 
214
Bronić A. et al. Survey on haemostasis testing in Croatian laboratories
porting coagulation critical values should be con-
sidered. 
Although most respondents stated that they were 
satisfied with the currently performed coagulation 
panel with respect to their medical facility needs, 
36.5% of laboratories, stated the need to intro-
duce additional tests. It is not surprising as most 
survey respondents were PHC laboratories that at 
present perform only PT. 
The main problems encountered in daily practice 
were mostly related to preanalytical issues, espe-
cially to inappropriate samples withdrawn at dis-
tant locations, as well as communication and col-
laboration between GPs, clinicians and laboratory 
staff related to anticoagulation therapy. Problem 
solving through personal contact and/or review-
ing available literature are equally important. More 
than half of respondents are not aware of the avail-
ability of the certain coagulation tests in other fa-
cilities, and most laboratories do not have a de-
fined protocol for sending coagulation samples to 
other medical facilities. A national referral policy 
for specialist’s investigations in bleeding and co-
agulation disorders should be set up in Croatia.
In summary, we believe that this survey has cov-
ered the most important aspects in the field of 
laboratory coagulation. However, although ques-
tionnaire responses were not obtained from all 
laboratories performing coagulation assays, al-
most all MBL from general hospitals, TLs and spe-
cial laboratories for haematology and coagulation 
providing higher number of coagulation tests to 
patients across the country, responded the survey. 
Therefore, the response rate for particular tests 
and aspects of testing is certainly higher than the 
overall response rate. The results highlight differ-
ent practice policies in particular areas of haemo-
stasis testing between Croatian laboratories and 
many important fields need improvement. Infor-
mation gathered in this survey will be the starting 
point for the development of national guidelines 
and recommendations on coagulation sample 
handling and global coagulation assays testing as 
well as corresponding result reporting.
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